Hopp til hovedinnhold

Sekundærforebygging ved iskemisk hjerte- og karsykdom

Sist oppdatert: Sist revidert:
Sist revidert av:


  • Helsedirektoratet. Nasjonal faglig retningslinje for forebygging av hjerte- og karsykdom. Oslo 2018. 
  • Gjennomgående meget høy kvalitet. Det er tallrike randomiserte, kontrollerte studier og systematiske oversikter
  1. Norsk hjerteinfarktregister. Årsrapport 2019. stolav.no  
  2. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72. Circulation  
  3. Dødsårsakregisteret 2018. Dødsfall av hjerte-karsykdommer. Siden besøkt 27.10.2020. statistikkbank.fhi.no  
  4. Beauchamp A, Talevski J, Niebauer J, et al. Health literacy interventions for secondary prevention of coronary artery disease: a scoping review. Open Heart 2022; 9: e001895. pmid:35064057 PubMed  
  5. Anderson L, Thompson DR, Oldridge N, et al. Exercise‐based cardiac rehabilitation for coronary heart disease. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.: CD001800. DOI: 10.1002/14651858.CD001800.pub3. DOI  
  6. Xia TL, Huang FY, Peng Y, et al. Efficacy of Different Types of Exercise-Based Cardiac Rehabilitation on Coronary Heart Disease: a Network Meta-analysis. J Gen Intern Med. 2018;33(12):2201-2209. PubMed  
  7. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. PMID: 27222591. PubMed  
  8. Helsedirektoratet. Nasjonal faglig retningslinje for forebygging av hjerte- og karsykdom. Sist faglig oppdatert 05. mars 2018. www.helsedirektoratet.no  
  9. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): A randomised controlled trial. Lancet 2022; 399:1876. PMID: 35525255 PubMed  
  10. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952-67. Circulation  
  11. Kwak SM, Myung SK, Lee YJ, et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012. PMID:22493407. PubMed  
  12. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: A systematic . Ann Intern Med 2014; 160: 398-406. doi:10.7326/M13-1788 DOI  
  13. Aung T,m Halsey J, Kromhout D, et al. Associatioin of omega-3 fatty acid supplement use with cardiovascular disease risks. Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol 2018. pmid:29387889 PubMed  
  14. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018; 7: CD003177. PMID: 30019766 PubMed  
  15. Hooper L, Al-Khudairy L, Abdelhamid AS, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018 Jul 18;7:CD011094. PMID: 30019765 PubMed  
  16. Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: A scientific statement from the American Heart Association. Circulation 2015; 131:927. doi: 10.1161/CIR.0000000000000182 DOI  
  17. Biddinger KJ, Emdin CA, Haas ME, et al. Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. JAMA Netw Open 2022; 5: e223849. doi:10.1001/jamanetworkopen.2022.3849 DOI  
  18. Patel A, MacMahon S, Chalmers J, et al., for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72. PubMed  
  19. Gerstein HC, Miller ME, Byington RP, et al., for the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59. New England Journal of Medicine  
  20. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91. New England Journal of Medicine  
  21. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008; 118: 1768-75. Circulation  
  22. Taylor CB, Youngblood ME, Catellier D, et al., for the ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792-8. PubMed  
  23. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289: 3106-16. Journal of the American Medical Association  
  24. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 2008; 300: 2161-71. Journal of the American Medical Association  
  25. Boersma E, Harrington RA, Moliterna DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98. PubMed  
  26. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86. British Medical Journal  
  27. Cea Soriano L, Gaist D, Soriano-Gabarro M, Bromley S. Low-dose aspirin and risk of intracranial bleeds: An observational study in UK general practice. Neurology. 2017 . PMID: 29093065 PubMed  
  28. Rothwell PM, Cook NR, Gaziano M, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018. pmid:30017552 PubMed  
  29. Charlot M, Grove EL, Hansen PR, et al. Protonpumpinhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690. BMJ (DOI)  
  30. Chiarito M, Sans-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 2020. doi:10.1016/S0140-6736(20)30315-9 DOI  
  31. Sundström J, Hedberg J, Aarskog P, et al. Low-dose aspirin discontinuation and risk of cardiovascular events. A swedish nationwide, population-based cohort study. Circulation 2017; 136: 1183-92. pmid:28947478 PubMed  
  32. Collet J-P, Hulot J-S, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-17. PubMed  
  33. Salpeter S, Ormiston T, Salpeter E, Wood-Baker R. Cardioselective beta-blockers for reversible airway disease. Cochrane Database of Systematic Reviews, issue 4, 2002. CD002992. Cochrane (DOI)  
  34. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015. doi:10.1056/NEJMoa1410489 DOI  
  35. Hagström E, Steg PG, Szarek M, et al. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation 2022. pmid:35770629 PubMed  
  36. Li J, Du H, Wang Y, et al. Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis. Heart 2022. pmid:35508401 PubMed  
  37. Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol 2019; 73: 2791-2802. pmid:30898607 PubMed  
  38. Gaba P, Bhatt DL, Steg PG, et al. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. J Am Coll Cardiol 2022; 79: 1660-71. pmid:35483753 PubMed  
  39. BMJ News. NICE endorses new drug to prevent myocardial infarctions and strokes. BMJ 2022; 377: o1444. doi:10.1136/bmj.o1444 DOI  
  40. Ridker PM, Rifai N, MacFadyen J, et al. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation 2022. pmid:35762321 PubMed  
  41. Koskinas KC;Siontis GCM;Piccolo R;Mavridis D;Raber.   Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2017 Oct 23. (Systematic Review)  PMID: 29069377 PubMed  
  42. Schmidt AF, Carter J-PL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas J. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2020, Issue 10. Art. No.: CD011748. DOI: 10.1002/14651858.CD011748.pub3. Accessed 02 February 2022. The Cochrane Library  
  43. Sabatine MS, Wiviott SD, Im K, et al. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: A meta-analysis. JAMA Cardiol 2018. PMID: 30073316 PubMed  
  44. Marston NA, Giugliano RP, Park J-G, et al et al. Cardiovascular benefit of lowering low-density lipoprotein cholesterol below 40 mg/dL. Circulation 2021 Nov 23; 144:1732. PMID: 34452583 PubMed  
  45. Brugts JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009; 30: 1385-94. PubMed  
  46. Potier L, Roussel R, Elbez Y, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 2017; 103: 1339-46. pmid:28285267 PubMed  
  47. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013 Oct 23;310(16):1711-20. PubMed  
  48. Conolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 391: 205-18. pmid:29132879 PubMed  
  49. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 391: 219-29. pmid:29132880 PubMed  
  50. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017. pmid:28845751 PubMed  
  51. Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2017. pmid:29146124 PubMed  
  52. Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA 2008; 300: 795-804. Journal of the American Medical Association  
  53. Albert CM, Cook NR, Gaziano M, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease. JAMA 2008; 299: 2027-36. PubMed  
  54. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1629-32. New England Journal of Medicine  
  55. Lonn E, Yusuf S, Arnold MJ, et al, for the Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77. New England Journal of Medicine  
  56. Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet 2020. pmid:PMID: 30771737 PubMed  
  57. Etminan M, Carleton B, Delaney JAC, Padwal R. Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy 2004; 24: 338-43. PubMed  
  58. Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022; 400: 1195-1205. doi:10.1016/S0140-6736(22)01657-9 DOI  
  59. Eagle KA, Guyton RA, Davidoff R, et al., for the American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American Society for Thoracic Surgery and the Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110: 1168-76. Circulation  
  60. Boden WE, O'Rourke RA, Teo KK, et al., for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-16. New England Journal of Medicine  
  61. Weintraub WS, Spertus JA, Kolm P, et al., for the COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008; 359: 677-87. New England Journal of Medicine  
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL